Programs In Recurrent Brain Cancer

Brain Cancer and Selective Immunotherapy

Tocagen™ believes that we are at the forefront of next generation therapeutics for treating brain cancer using selective immunotherapeutic products that are based on gene therapy technology.

We are initially focused on an aggressive type of brain cancer, namely recurrent High Grade Glioma (HGG), which includes Glioblastoma Multiforme (GBM) and anaplastic astrocytomas.

Toca 511 & Toca FC

Toca 511, the key novel component of Tocagen’s first Product Candidate (Toca 511 & Toca FC), was developed using our breakthrough retroviral replicating vector platform. Tocagen is currently investigating Toca 511 & Toca FC in clinical trials with patients who have recurrent High Grade Gliomas (HGG). Tocagen is also considering the study of Toca 511 & Toca FC in patients with newly diagnosed (primary) brain cancer and in patients with cancers that have metastasized to the brain, liver and lung from other advanced cancers including breast, lung, colorectal, prostate and melanoma.

Learn more about brain cancer:

Product Candidates
Toca 511 & Toca FC

Also see:
Tocagen’s Technology